Medinotec Inc.

Medinotec Inc. is a Nevada-based medical device group that sells and distributes surgical and vascular products, with operating roots in South Africa through its subsidiary DISA Medinotec. The company combines in-house manufacturing and product development with distributor-led commercialization, and it is now using FDA-cleared products to expand in the United States and other international markets.

12,1 %

52,7 %

8,2 %

+6,8 %

5.83

5.83

— Medinotec Inc.
%
Proprietary medical devices45% In-house developed devices such as the Trachealator and OutFlo catheter sold under the Medinotec platform.
Vascular and cardiology products25% Products used in coronary and vascular procedures, including stents and balloon catheter applications.
Distributed product ranges20% Third-party or partner-sourced medical devices distributed through the company’s sales network.
Manufacturing and commercialization services10% Internal manufacturing, product development, and commercialization support tied to device launches.

Medinotec sells primarily to hospitals, healthcare providers, and distributor partners that serve operating rooms and...

  • Hospitals and surgical centersprimary

    Buy devices for operating room and procedural use, especially where standardization, reliability, and clinical outcomes matter.

  • Distributor partnersprimary

    Purchase or place products into local markets and are critical to Medinotec’s sales reach, especially in South Africa.

  • Healthcare systems and physician networkssecondary

    Adopt products when they improve procedures, support cost containment, and fit hospital purchasing programs.

  • U.S. market customersemerging

    Early commercial buyers of FDA-cleared products such as Trachealator and OutFlo as the company expands in North America.

The company’s operating base and historical revenue engine are in South Africa, where it has a large distributor...

  • South Africa is the core operating and distribution market
  • United States is the main expansion market after FDA clearances
  • Sales also reach the Middle East, South America, Europe, and Asia
  • South African distribution network covers about 60% of OR floors weekly
  • Currency exposure includes the South African rand and U.S. dollar

Medinotec’s strategy is to broaden its product range, build operating capabilities, and use strategic acquisitions to...

01
U.S. commercialization of FDA-cleared productsshort-term

Diversifies revenue away from South Africa and opens a larger, higher-value market.

02
Distributor network replicationmedium-term

The company’s South African model depends on distributor reach and hospital access.

03
Selective product and capability expansionmedium-term

Broader product breadth improves customer stickiness and reduces concentration risk.

The biggest business risk is customer and geographic concentration, especially reliance on South African distributors...

high

Customer concentration

A significant portion of sales depends on a small number of distributors and customers.

Scope
South Africa and export channels
Materiality
high
high

Regulatory approval risk

U.S. and other developed markets require approvals before commercialization.

Scope
FDA and local market registrations
Materiality
high
high

Political and infrastructure risk in South Africa

Power supply, political instability, and transfer restrictions can disrupt operations.

Scope
Manufacturing and cash movement
Materiality
high
medium

Competitive pressure

The company competes with larger, better-capitalized medical device groups.

Scope
Pricing, product breadth, and distribution
Materiality
high
medium

Foreign exchange volatility

Operations and sales span the South African rand and U.S. dollar.

Scope
Working capital, revenue translation, and margins
Materiality
medium
Revenue recognition
Can shift quarterly revenue and gross profit timing
Inventory valuation and obsolescence
Can affect cost of sales and working capital
Allowance for note receivable impairment
Can reduce reported assets and earnings
Foreign currency translation
Can affect revenue, expenses, and equity translation
Related-party financing
Can affect leverage, cash flow, and financing risk

: 28/04/2026